Syncell, a Taipei, Taiwan- and Watertown, MA-based company which specializes in new subcellular protein purification and spatial proteomics analysis, raised $15M in Series A funding.
The round was led by Taiwania Capital, with participation from new and existing investors.
The company intends to use the funds to expand and accelerate the global commercialization and commercial support for its Microscoop platform.
Led by CEO and Founder Jung-Chi, Syncell is a commercial stage life science company focused on subcellular protein purification and spatial proteomics analysis. It has commercialized its Microscoop® technology, helping researchers achieve unbiased discovery in spatial proteomics at the disease site, with the ability to accurately discover new protein components from targeted regions of interest.
The Microscoop platform enables high-precision, unbiased, spatial proteomic discovery in subcellular tissues or cells, and has the ability to accurately discover new protein components from predetermined regions of interest. The technology also enables spatial protein purification for proteomic discovery, helping researchers identify cell subtypes and states, novel protein drug targets at disease-associated locations, biomarkers for disease, and mechanisms of biological pathways.
The company expects to place Microscoop Mint instruments in the U.S., Europe, and Asia by the end of the year as it builds its commercial infrastructure to support customers worldwide.
FinSMEs
11/12/2024